准CDK2通过驱动老在无塑性甲状腺癌中的老化,使得伦瓦替尼易易受攻击
Ben Ma1,2, Youzhou Sang2,3, Xiaoxue Du1,2
1Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 24, 2024
概括
将伦瓦替尼与CDK2抑制剂相结合,为治疗形甲状腺癌 (ATC) 提供了一种新的策略. 这种方法通过抑制CDK2,这是抵抗的关键因素,以向伦瓦替尼抗性瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 无塑性甲状腺癌 (ATC) 具有高度致命性,而伦瓦提尼布耐药性构成了重大的临床挑战.
- 伦瓦提尼布用于治疗ATC,但对抗性病例的有效治疗选择有限.
研究的目的:
- 为了确定有效的组合疗法来治疗耐伦瓦提尼布的形甲状腺癌.
- 研究CDK2在伦瓦提尼布耐药性中的作用,并探索CDK2抑制作为治疗策略.
主要方法:
- 来自ATC的患者衍生细胞和异种移植被确定.
- 进行了高通量药物选和协同效应分析.
- 评估了细胞功能 (衰老,细胞亡,细胞周期,活力);分析了CDK2表达和降解途径.
主要成果:
- 通过抑制CDK2,伦瓦替尼表现出合成致死性,抑制细胞周期过渡并诱导ATC的衰老.
- 高CDK2表达与伦瓦替尼布耐药性和患者的不良结果相关.
- 伦瓦提尼布通过RACK1-FBW7复合体破坏其降解,从而增加了CDK2蛋白水平.
- 与伦瓦提尼布和CDK2抑制剂的联合治疗抑制了耐药模型中的异种移植瘤生长.
结论:
- 抑制CDK2是一种有前途的治疗策略,用于抗伦瓦替尼的ATC.
- 将伦瓦提尼布与CDK2抑制剂结合使用,可以在CDK2表达高的患者中克服耐药性.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


